Marinova reports two clinical studies in pipeline
Marinova has some exciting news to report in the area of new clinical trials. Reflecting a commitment to developing novel fucoidan compounds with proven therapeutic efficacy, they have just commenced two new clinical trials. These two studies will investigate the potential of Maritech® fucoidan in the following clinical settings:
• Osteoarthritis and Inflammation
This is a large multi-site trial, directly commissioned by Marinova, to assess the ability of Maritech® fucoidan to reduce the symptoms of osteoarthritis. The trial is double randomised, placebo controlled and – in addition to pain score testing – serum samples will be tested for several key markers of inflammation. This study is being conducted at Southern Cross University (Australia) and results are expected in the second quarter of 2012.
• Integrative Oncology
At two centres in Australia, cancer patients undergoing chemotherapy for breast cancer will take Maritech® fucoidan. The levels of chemotherapy drug in serum will be measured to assess the effects of fucoidan, including any interactions with the chemotherapy drug. Indicators of pain and improvements in quality of life will also be assessed. This study is being conducted in conjunction with the University of Tasmania and is scheduled for completion at the end of 2013.